News

Publish Date
PERA 2025 Debated in Senate IP Subcommittee Hearing, with Business Methods, Diagnostics in Focus
US Senate continues uphill battle on patent eligibility bill
How impactful is the new USPTO director’s S101 decision?
Amgen Attacks Academics’ False Claims About Biologic Patents
C4IP Publishes Website Addressing Misinformation Published by I-MAK
USPTO gets new director as John Squires secures Senate confirmation
Senate Confirms Squires To Lead USPTO
China pharma deals threaten U.S. biotech
C4IP Urges FTC to Proceed with Caution on Addressing Perceived Drug Pricing Problems
What Attys Want To Know About Lutnick’s Harvard IP Threat
Potential impact of US government march-in on Harvard’s patents
Patent Judges Review Fewer Challenges as Agency Priorities Shift
Scroll to Top